RTSNRetension Pharmaceuticals
临床阶段生物制药公司，开发治疗高血压等心血管疾病的药物。
$12发行价
$46M融资额
$10.53首日收盘
-12.25%首日表现
临床阶段生物制药公司，开发治疗高血压等心血管疾病的药物。
公司简介（来源：StockAnalysis）
Retension Pharmaceuticals, Inc. operates as a clinical -stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. It offers RTN -001, an oral, small molecule phosphodiesterase -5 inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling. The company was incorporated in 2023 and is headquartered in Falls Church, Virginia.
51CFO 判断：需兼具临床开发财务管控、FDA监管资本规划及早期biotech融资节奏把控能力。
管理层与创始团队详情以 SEC 招股书披露为准
你的公司需要这样的 CFO 吗？
51CFO 是专注美股市场的投行团队：赴美 IPO、借壳上市、壳公司买卖、SPAC 与 De-SPAC、SEC 申报与上市后再融资，从架构到敲钟一条龙操盘。免费 30 分钟上市路径诊断，24 小时内回复。
预约咨询